Mutations in genes involved in HRR are associated with better outcomes after PARPi therapy in prostate cancer15, but it is unclear which tumor genetic or genomic factors might influence PARPi response in patients with human epidermal growth factor receptor 2-negative (HER2−), gBRCA1/2mut locally advanced or metastatic breast cancer (MBC). Here, ERBB2 is linked to neoplasm.